Kerepesi, Csaba
Bakacs, Tibor
Moss, Ralph W.
Slavin, Shimon
Anderson, Colin C. http://orcid.org/0000-0003-1733-4237
Funding for this research was provided by:
Ministry of Human Capacities in Hungary (2018-1.2.1-NKP-00008)
Canadian Institutes of Health Research (PS148588)
Article History
Received: 20 November 2019
Accepted: 21 February 2020
First Online: 9 March 2020
Compliance with ethical standards
:
: TB is a partner and CSO of PRET Therapeutics Ltd, developing the patented low-dose ICI combination therapy. All other authors have none to declare.
: This study was exempt from ethical review because all analyzed datasets are deidentified and publicly available.
: Not applicable.